open access
Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report
, 12, 23, 4, 3
Affiliations- Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
- Heart Failure Department, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
- Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
- Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
open access
Abstract
Abstract
About this articleTitle
Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report
Journal
Issue
Article type
Research Letter
Pages
157-159
Published online
2021-09-30
Page views
5676
Article views/downloads
681
DOI
10.5603/CJ.a2021.0119
Pubmed
Bibliographic record
Cardiol J 2022;29(1):157-159.
Authors
Henrik Fox
Jan F. Gummert
Philipp Sommer
Cornelius Knabbe
Christian Sohns
References (10)- Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020; 5(7): 831–840.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020; 323(16): 1561–1562.
- Gyoten T, Rojas SV, Irimie A, et al. Patients with ventricular assist device and cerebral entrapment-Supporting skullcap reimplantation. Artif Organs. 2021; 45(5): 473–478.
- Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019; 40(44): 3626–3644.
- Gyoten T, Morshuis M, Rojas SV, et al. Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices. J Artif Organs. 2021; 24(2): 173–181.
- Flottmann C, Dumitrescu D, Sohns C, et al. Addition of levosimendan to overcome acute cardiogenic shock-Paving the way for later heart transplantation-A first case report. Clin Case Rep. 2021; 9(2): 856–860.
- Szymczyk T, Sauzet O, Paluszkiewicz LJ, et al. Non-invasive assessment of central venous pressure in heart failure: a systematic prospective comparison of echocardiography and Swan-Ganz catheter. Int J Cardiovasc Imaging. 2020; 36(10): 1821–1829.
- Mehta R, Leimberger J, Diepen Sv, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017; 376(21): 2032–2042.
- Gordon A, Perkins G, Singer M, et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med. 2016; 375(17): 1638–1648.
